MOLECULAR INFORMATION
Molecular information
- Length
- 3 amino acids
- Type
- Tripeptide bioregulator · claimed pineal gland modulator and neuroprotective
Amino acid sequence
Glu-Asp-Arg Pinealon is one of the Khavinson family of “short bioregulator peptides” — a series of di-, tri- and tetrapeptides developed at the St. Petersburg Institute of Bioregulation and Gerontology. The published literature on this family is large but originates almost entirely from one group.
Claims vs evidence
- Neuroprotection / cognitive support — preclinical only, single-group
- Pineal-gland modulation — claimed mechanism, not independently confirmed
- Anti-ageing / lifespan extension — extrapolated from animal studies
Why we grade it D
The same pattern as Epitalon and the other Khavinson peptides: extensive single-source literature with no independent Western replication. The underlying “bioregulator” framework — that short peptides act as tissue-specific genetic regulators — is not part of mainstream pharmacological consensus. We grade the compound family as D until independent replication appears.
Frequently asked questions
- What is Pinealon?
- A short tripeptide (Glu-Asp-Arg) developed by Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology in the 1990s-2000s. Claimed to be a "tissue-specific bioregulator" of the pineal gland with neuroprotective and anti-ageing effects.
- Is Pinealon authorised anywhere?
- No — no Western regulator (EMA, FDA, MHRA) has authorised Pinealon. Sold exclusively through grey-market peptide channels, often via Russian-language vendors.
- Why does Peptidepedia grade it D?
- The published evidence comes almost entirely from one research group, in one country, over decades. Independent Western replication is absent. The "tissue-specific bioregulator" framework is not recognised by mainstream pharmacology.